Patents by Inventor Peter H. Krammer

Peter H. Krammer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of the function of the core domain of annexins, and uses thereof in autoimmune and/or cancer therapy
    Publication number: 20180275124
    Abstract: The present invention relates to a method for identifying a compound that modulates the interaction of an annexin core domain with a receptor selected from the group of C-type lectin receptors and LRP-1 in a cell, and uses thereof in autoimmune and/or cancer therapy.
    Type: Application
    Filed: November 19, 2015
    Publication date: September 27, 2018
    Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Inventors: Peter H. KRAMMER, Alexandra KURZ, Björn LINKE, Heiko WEYD
  • COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER
    Publication number: 20160374983
    Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
    Type: Application
    Filed: June 29, 2016
    Publication date: December 29, 2016
    Inventors: Min LI-WEBER, Peter H. Krammer
  • TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY
    Publication number: 20160287553
    Abstract: The present invention relates to an inhibitor of protein translation for use in high-dose chemotherapy and/or high-dose radiotherapy of disease; to an inhibitor of protein translation for use in a combination therapy comprising high-dose chemotherapy and/or high-dose radiotherapy of disease; and to an inhibitor of protein translation for use in preventing adverse effects of high-dose chemotherapy and/or high-dose radiotherapy or for preventing radiation syndrome in a subject.
    Type: Application
    Filed: November 21, 2014
    Publication date: October 6, 2016
    Inventors: Michael S. BECKER, Min LI-WEBER, Peter H. KRAMMER
  • Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
    Patent number: 9387192
    Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: July 12, 2016
    Assignee: DKFZ DEUTCHERS KREBSFORSCHUNGSZENTRUM
    Inventors: Min Li-Weber, Peter H. Krammer
  • Methods and compounds for treating diseases caused by reactive oxygen species
    Patent number: 8563500
    Abstract: Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the complex I-mediated ROS production, a medicament containing such compound and methods for screening for such compounds.
    Type: Grant
    Filed: September 5, 2007
    Date of Patent: October 22, 2013
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Karsten Guelow, Marcin Kaminski, Michael Kiessling, Peter H. Krammer
  • COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER
    Publication number: 20110250166
    Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
    Type: Application
    Filed: November 20, 2009
    Publication date: October 13, 2011
    Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Min Li-Weber, Peter H. Krammer
  • METHODS AND COMPOUNDS FOR TREATING DISEASES CAUSED BY REACTIVE OXYGEN SPECIES
    Publication number: 20100305187
    Abstract: Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the complex I-mediated ROS production, a medicament containing such compound and methods for screening for such compounds.
    Type: Application
    Filed: September 5, 2007
    Publication date: December 2, 2010
    Applicant: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Karsten Guelow, Marcin Kaminski, Michael Kiessling, Peter H. Krammer
  • Monoclonal antibodies to the APO-1 antigen
    Patent number: 5891434
    Abstract: The APO-1 cellular membrane antigen, an about 50 kDa antigen associated with cellular apoptosis, and purified cDNA encoding same is described. The antigen is expressed by numerous normal and malignant cells, including activated and malignant lymphoid cells. Also disclosed are antibodies which bind the antigen, and which induce growth inhibition and apoptosis.
    Type: Grant
    Filed: March 23, 1995
    Date of Patent: April 6, 1999
    Assignee: Centocor, Inc.
    Inventors: Peter H. Krammer, Klaus-Michael Debatin, Bernhard C. Trauth, Iris Behrmann, Jens Dhein, Christiane Klas, Peter Moller, Werner Falk, Alexander Oehm, Peter T. Daniel